Suboptimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy


      To investigate the correlation of multiparametric magnetic resonance imaging targeted (TBx) and/or systematic prostate biopsy (SBx) in predicting the presence of clinically significant (cs) prostate cancer (PCa) in radical prostatectomy (RP) specimens. Concordance of mpMRI and RP specimen lesions was also investigated in terms of tumor localization and histopathological features.


      A total of 70 male patients with PCa and treated with robot-assisted RP were included in this study between January 2016 and December 2019. All patients underwent mpMRI-TBx and concomitant SBx. Suspicious lesions on mpMRI were scored according to Prostate Imaging-Reporting and Data System version 2 (PI-RADS) criteria. TBx was performed for all suspicious lesions with a PI-RADS score ≥3.


      The median age was 67 (43-77) years. Presence of csPCa in prostatectomy specimens was missed by TBx and SBx specimens in 25.4% and 19.4% of the cases, respectively (P<.001, for each). Combination of both biopsy (CBx) results improved detection by missing only 4.5% of csPCa (P = .250). International Society of Urologic Pathology grade group concordance with RP specimens were 50%, 54.3% and 67.1% for SBx, TBx, and CBx, respectively. There was a statistically significant correlation in terms of tumor localization and histopathological features between prostatectomy specimens and the first 3 lesions, particularly for the index lesions.


      CBx improved detection rate of csPCa. We propose TBx of 3 lesions with highest PI-RADS score(s) and a combination with SBx for the highest correlation with prostatectomy histopathology.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mottet N
        • van den Bergh RCN
        • Briers E
        • et al.
        EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020.
        European Association of Urology Guidelines. 2020 Edition. European Association of Urology Guidelines Office, Arnhem, The Netherlands2020 (Vol presented at the EAU Annual Congress Amsterdam 2020)
        • Venderink W
        • van Luijtelaar A
        • Bomers JGR
        • et al.
        Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer.
        Eur Urol. 2018; 73: 353-360
        • Choi YH
        • Kang MY
        • Sung HH
        • et al.
        Comparison of cancer detection rates between TRUS-guided biopsy and MRI-targeted biopsy according to PSA level in biopsy-naive patients: a propensity score matching analysis.
        Clin Genitourin Cancer. 2019; 17: e19-e25
        • Tu X
        • Liu Z
        • Zhang C
        • et al.
        Diagnostic role of magnetic resonance imaging-targeted biopsy for prostate cancer in biopsy-naive men: a meta-analysis.
        Urol Int. 2020; 104: 187-198
        • Turkbey B
        • Brown AM
        • Sankineni S
        • Wood BJ
        • Pinto PA
        • Choyke PL
        Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer.
        CA Cancer J Clin. 2016; 66: 326-336
        • van der Leest M
        • Cornel E
        • Israel B
        • et al.
        Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study.
        Eur Urol. 2019; 75: 570-578
        • Kasivisvanathan V
        • Rannikko AS
        • Borghi M
        • et al.
        MRI-targeted or standard biopsy for prostate-cancer diagnosis.
        N Engl J Med. 2018; 378: 1767-1777
        • Siddiqui MM
        • Rais-Bahrami S
        • Turkbey B
        • et al.
        Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
        JAMA. 2015; 313: 390-397
        • Rouviere O
        • Puech P
        • Renard-Penna R
        • et al.
        Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.
        Lancet Oncol. 2019; 20: 100-109
        • Turkbey B
        • Mani H
        • Shah V
        • et al.
        Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.
        J Urol. 2011; 186: 1818-1824
        • Isebaert S
        • Van den Bergh L
        • Haustermans K
        • et al.
        Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology.
        J Magn Reson Imaging. 2013; 37: 1392-1401
        • Le JD
        • Tan N
        • Shkolyar E
        • et al.
        Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology.
        Eur Urol. 2015; 67: 569-576
        • Alshak MN
        • Patel N
        • Gross MD
        • Margolis D
        • Hu JC
        Persistent discordance in grade, stage, and NCCN risk stratification in men undergoing targeted biopsy and radical prostatectomy.
        Urology. 2020; 135: 117-123
        • Porpiglia F
        • S DEL
        • Passera R
        • et al.
        Multiparametric-magnetic resonance/ultrasound fusion targeted prostate biopsy improves agreement between biopsy and radical prostatectomy Gleason score.
        Anticancer Res. 2016; 36: 4833-4839
        • Gandaglia G
        • Ploussard G
        • Valerio M
        • et al.
        The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy.
        Eur Urol. 2020; 77: 733-741
        • Rosenkrantz AB
        • Ginocchio LA
        • Cornfeld D
        • et al.
        Interobserver reproducibility of the PI-RADS version 2 lexicon: a multicenter study of six experienced prostate radiologists.
        Radiology. 2016; 280: 793-804
        • Weinreb JC
        • Barentsz JO
        • Choyke PL
        • et al.
        PI-RADS prostate imaging - reporting and data system: 2015, version 2.
        Eur Urol. 2016; 69: 16-40
        • Johnson DC
        • Raman SS
        • Mirak SA
        • et al.
        Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging.
        Eur Urol. 2019; 75: 712-720
        • Özgen MB
        • Özveren B
        • Uzel S
        • Altuğ U
        • Türkeri L
        Initial outcomes and assessment of the transperineal multiparametric-magnetic resonance imaging/ultrasonography fusion biopsy method in diagnosing clinically-significant prostate cancer.
        Bull Urooncol. 2017; 16: 42
        • Epstein JI
        • Egevad L
        • Amin MB
        • et al.
        The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system.
        Am J Surg Pathol. 2016; 40: 244-252
        • Epstein JI
        • Walsh PC
        • Carmichael M
        • Brendler CB
        Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
        JAMA. 1994; 271: 368-374
        • Shoag JE
        • Cai PY
        • Gross MD
        • et al.
        Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance.
        Cancer. 2020; 126: 2986-2990
        • Drost FH
        • Osses D
        • Nieboer D
        • et al.
        Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a cochrane systematic review and meta-analysis.
        Eur Urol. 2020; 77: 78-94
        • Westhoff N
        • Baessler B
        • von Hardenberg J
        • et al.
        Systematic prostate biopsy still matters: a comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications.
        Urol Oncol. 2019; 37: 678-687
        • Ahdoot M
        • Wilbur AR
        • Reese SE
        • et al.
        MRI-Targeted, systematic, and combined biopsy for prostate cancer diagnosis.
        N Engl J Med. 2020; 382: 917-928
        • Shapiro RH
        • Johnstone PA
        Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance.
        Urology. 2012; 80: 661-666
        • Cohen MS
        • Hanley RS
        • Kurteva T
        • et al.
        Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis.
        Eur Urol. 2008; 54: 371-381
        • Goel S
        • Shoag JE
        • Gross MD
        • et al.
        Concordance between biopsy and radical prostatectomy pathology in the Era of targeted biopsy: a systematic review and meta-analysis.
        Eur Urol Oncol. 2020; 3: 10-20
        • Pepe P
        • Garufi A
        • Priolo GD
        • Galia A
        • Fraggetta F
        • Pennisi M
        Is it time to perform only magnetic resonance imaging targeted cores? Our experience with 1,032 men who underwent prostate biopsy.
        J Urol. 2018; 200: 774-778
        • Mouraviev V
        • Villers A
        • Bostwick DG
        • Wheeler TM
        • Montironi R
        • Polascik TJ
        Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.
        BJU Int. 2011; 108: 1074-1085